Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the pediatric preclinical testing program

Richard B. Lock, Hernan Carol, John M. Maris, Min H. Kang, C. Patrick Reynolds, E. Anders Kolb, Richard Gorlick, Stephen T. Keir, Catherine A. Billups, Raushan T. Kurmasheva, Peter J. Houghton, Malcolm A. Smith

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Ganetespib, an Hsp90 inhibitor, was tested against the PPTP in vitro cell line panel and selected xenografts in vivo, including JAK2- and BRAF-mutated models. Ganetespib demonstrated potent in vitro cytotoxic activity (median rIC50 8.8nM, range 4.4-27.1nM). In vivo, ganetespib induced significant differences in EFS distribution for 4 of 11 xenografts. Intermediate activity (EFS T/C>2) was noted only for the MV4;11 xenograft, and there were no objective responses. Administered as single agents, Hsp90 inhibitors examined by the PPTP have shown limited evidence for a therapeutic window against both solid tumor and leukemia pediatric preclinical models.

Original languageEnglish (US)
JournalPediatric Blood and Cancer
Volume60
Issue number7
DOIs
StatePublished - Jul 2013

Fingerprint

Heterografts
Pediatrics
Leukemia
Cell Line
STA 9090
Neoplasms
N-propyl-4-phenyl-1,2,3,6-tetrahydropyridine
In Vitro Techniques
Therapeutics

Keywords

  • Developmental therapeutics
  • Hsp90 inhibitors
  • Preclinical testing

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

Lock, R. B., Carol, H., Maris, J. M., Kang, M. H., Reynolds, C. P., Kolb, E. A., ... Smith, M. A. (2013). Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the pediatric preclinical testing program. Pediatric Blood and Cancer, 60(7). https://doi.org/10.1002/pbc.24451

Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the pediatric preclinical testing program. / Lock, Richard B.; Carol, Hernan; Maris, John M.; Kang, Min H.; Reynolds, C. Patrick; Kolb, E. Anders; Gorlick, Richard; Keir, Stephen T.; Billups, Catherine A.; Kurmasheva, Raushan T.; Houghton, Peter J.; Smith, Malcolm A.

In: Pediatric Blood and Cancer, Vol. 60, No. 7, 07.2013.

Research output: Contribution to journalArticle

Lock, RB, Carol, H, Maris, JM, Kang, MH, Reynolds, CP, Kolb, EA, Gorlick, R, Keir, ST, Billups, CA, Kurmasheva, RT, Houghton, PJ & Smith, MA 2013, 'Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the pediatric preclinical testing program', Pediatric Blood and Cancer, vol. 60, no. 7. https://doi.org/10.1002/pbc.24451
Lock, Richard B. ; Carol, Hernan ; Maris, John M. ; Kang, Min H. ; Reynolds, C. Patrick ; Kolb, E. Anders ; Gorlick, Richard ; Keir, Stephen T. ; Billups, Catherine A. ; Kurmasheva, Raushan T. ; Houghton, Peter J. ; Smith, Malcolm A. / Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the pediatric preclinical testing program. In: Pediatric Blood and Cancer. 2013 ; Vol. 60, No. 7.
@article{f5936e7fe28d47bea6a17208daf34ed8,
title = "Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the pediatric preclinical testing program",
abstract = "Ganetespib, an Hsp90 inhibitor, was tested against the PPTP in vitro cell line panel and selected xenografts in vivo, including JAK2- and BRAF-mutated models. Ganetespib demonstrated potent in vitro cytotoxic activity (median rIC50 8.8nM, range 4.4-27.1nM). In vivo, ganetespib induced significant differences in EFS distribution for 4 of 11 xenografts. Intermediate activity (EFS T/C>2) was noted only for the MV4;11 xenograft, and there were no objective responses. Administered as single agents, Hsp90 inhibitors examined by the PPTP have shown limited evidence for a therapeutic window against both solid tumor and leukemia pediatric preclinical models.",
keywords = "Developmental therapeutics, Hsp90 inhibitors, Preclinical testing",
author = "Lock, {Richard B.} and Hernan Carol and Maris, {John M.} and Kang, {Min H.} and Reynolds, {C. Patrick} and Kolb, {E. Anders} and Richard Gorlick and Keir, {Stephen T.} and Billups, {Catherine A.} and Kurmasheva, {Raushan T.} and Houghton, {Peter J.} and Smith, {Malcolm A.}",
year = "2013",
month = "7",
doi = "10.1002/pbc.24451",
language = "English (US)",
volume = "60",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "7",

}

TY - JOUR

T1 - Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the pediatric preclinical testing program

AU - Lock, Richard B.

AU - Carol, Hernan

AU - Maris, John M.

AU - Kang, Min H.

AU - Reynolds, C. Patrick

AU - Kolb, E. Anders

AU - Gorlick, Richard

AU - Keir, Stephen T.

AU - Billups, Catherine A.

AU - Kurmasheva, Raushan T.

AU - Houghton, Peter J.

AU - Smith, Malcolm A.

PY - 2013/7

Y1 - 2013/7

N2 - Ganetespib, an Hsp90 inhibitor, was tested against the PPTP in vitro cell line panel and selected xenografts in vivo, including JAK2- and BRAF-mutated models. Ganetespib demonstrated potent in vitro cytotoxic activity (median rIC50 8.8nM, range 4.4-27.1nM). In vivo, ganetespib induced significant differences in EFS distribution for 4 of 11 xenografts. Intermediate activity (EFS T/C>2) was noted only for the MV4;11 xenograft, and there were no objective responses. Administered as single agents, Hsp90 inhibitors examined by the PPTP have shown limited evidence for a therapeutic window against both solid tumor and leukemia pediatric preclinical models.

AB - Ganetespib, an Hsp90 inhibitor, was tested against the PPTP in vitro cell line panel and selected xenografts in vivo, including JAK2- and BRAF-mutated models. Ganetespib demonstrated potent in vitro cytotoxic activity (median rIC50 8.8nM, range 4.4-27.1nM). In vivo, ganetespib induced significant differences in EFS distribution for 4 of 11 xenografts. Intermediate activity (EFS T/C>2) was noted only for the MV4;11 xenograft, and there were no objective responses. Administered as single agents, Hsp90 inhibitors examined by the PPTP have shown limited evidence for a therapeutic window against both solid tumor and leukemia pediatric preclinical models.

KW - Developmental therapeutics

KW - Hsp90 inhibitors

KW - Preclinical testing

UR - http://www.scopus.com/inward/record.url?scp=84878264535&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878264535&partnerID=8YFLogxK

U2 - 10.1002/pbc.24451

DO - 10.1002/pbc.24451

M3 - Article

C2 - 23303741

AN - SCOPUS:84878264535

VL - 60

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 7

ER -